Radioimmunotherapy in Prostate Cancer Using 177Lu-J591 Antibody

Inclusion Criteria * Histologic diagnosis (recent or remote) of prostate adenocarcinoma * Progressive, castrate metastatic carcinoma of the prostate defined by presence of metastatic disease on imaging and: * progressive tumor lesions on CT or MRI and/or * new osseus lesions on bone scan and/or * rising PSA * Rising PSA on 3 serial determinations over a period of greater than 2 weeks. An increase in PSA must be determined by two separate measurements taken at least one week apart and confirmed by a third and if necessary, a fourth measurement. If the third measurement is not greater than the second, then a fourth measurement must be taken. The fourth measurement must be greater than the second measurement for the patients to be eligible for enrollment in the study. The minimum final PSA must be \> 2. * For subjects who have not undergone surgical orchiectomy, LHRH agonist or antagonist therapy must me maintained for the duration of this study * Platelet count \> 150,000/mm3 * Absolute neutrophil count (ANC) ≥ 2,000/mm3 * Normal coagulation profile (defined as PT or INR and PTT \< 1.3x ULN), unless on a stable anticoagulation regimen * Hematocrit \> 27% or Hemoglobin \> 9 g/dL without blood transfusion dependency * Patients of child bearing potential must agree to use an effective method of contraception * Patient must have progressed following discontinuation of anti-androgen therapy, if received * Serum testosterone \< 50 ng/ml Exclusion Criteria * Prior corti…